Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of cou...
- Autores:
-
De la Hoz Restrepo, Fernando
Alvis Guzman, Nelson
De la Hoz Gomez, Alejandro
Ruiz, Cuauhtémoc
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2017
- Institución:
- Corporación Universidad de la Costa
- Repositorio:
- REDICUC - Repositorio CUC
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.cuc.edu.co:11323/4721
- Acceso en línea:
- https://hdl.handle.net/11323/4721
https://repositorio.cuc.edu.co/
- Palabra clave:
- Papillomavirus vaccines
Health policy
Health services research
Program evaluation
Immunization programs
West Indies
Latin America
Vacunas contra el virus del papiloma
Política de salud
Investigación en servicios de salud
Programa de evaluación
Programas de inmunizacion
Indias Occidentales
América latina
- Rights
- openAccess
- License
- Attribution-NonCommercial-ShareAlike 4.0 International
id |
RCUC2_4c97535329f7f46da82050dd64b8cd38 |
---|---|
oai_identifier_str |
oai:repositorio.cuc.edu.co:11323/4721 |
network_acronym_str |
RCUC2 |
network_name_str |
REDICUC - Repositorio CUC |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
dc.title.translated.spa.fl_str_mv |
Políticas y procesos para el humano. vacunación contra el virus del papiloma en latín América y el caribe |
title |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
spellingShingle |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean Papillomavirus vaccines Health policy Health services research Program evaluation Immunization programs West Indies Latin America Vacunas contra el virus del papiloma Política de salud Investigación en servicios de salud Programa de evaluación Programas de inmunizacion Indias Occidentales América latina |
title_short |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
title_full |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
title_fullStr |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
title_full_unstemmed |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
title_sort |
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean |
dc.creator.fl_str_mv |
De la Hoz Restrepo, Fernando Alvis Guzman, Nelson De la Hoz Gomez, Alejandro Ruiz, Cuauhtémoc |
dc.contributor.author.spa.fl_str_mv |
De la Hoz Restrepo, Fernando Alvis Guzman, Nelson De la Hoz Gomez, Alejandro Ruiz, Cuauhtémoc |
dc.subject.spa.fl_str_mv |
Papillomavirus vaccines Health policy Health services research Program evaluation Immunization programs West Indies Latin America Vacunas contra el virus del papiloma Política de salud Investigación en servicios de salud Programa de evaluación Programas de inmunizacion Indias Occidentales América latina |
topic |
Papillomavirus vaccines Health policy Health services research Program evaluation Immunization programs West Indies Latin America Vacunas contra el virus del papiloma Política de salud Investigación en servicios de salud Programa de evaluación Programas de inmunizacion Indias Occidentales América latina |
description |
Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of countries in Latin America and the Caribbean (LAC). Methods. We reviewed national and regional sources of information to identify LAC countries with and without universal HPV vaccination, along with the year of introduction, type of HPV vaccine, vaccination scheme, age groups targeted, and coverage level reached. Incidence rates of cervical cancer were compared across countries with and without an HPV vaccination program, in order to identify inequities in access to HPV vaccines. Results. So far, 10 LAC countries have supplied data on their vaccination policies and vaccination coverage rates to the Pan America Health Organization. The majority of those 10 started their vaccination programs using quadrivalent vaccine. Only Chile, Ecuador, and Mexico started their programs using a two-dose scheme. However, by the end of 2016, most of the other countries had switched from a three-dose to a two-dose scheme. Different age groups are targeted in the various programs. Some countries vaccinate one-year birth cohorts, while others vaccinate multiple-year birth cohorts. By the end of 2014, coverage with at least two doses ranged from a low of 2% to a high of 86%. With the exception of Venezuela, the LAC countries with the largest populations introduced universal HPV vaccination between 2010 and 2014. Despite the progress that has occurred in some LAC countries, there are still 10 LAC nations with cervical cancer rates above the LAC average (21.2 cases per 100 000) that have not introduced an HPV vaccine in their EPI. Conclusions. With several key adjustments, HPV vaccination programs across Latin America and the Caribbean could be substantially strengthened. Ongoing monitoring of HPV infection outcomes is needed in order to assess the impact of different vaccination policies. |
publishDate |
2017 |
dc.date.issued.none.fl_str_mv |
2017 |
dc.date.accessioned.none.fl_str_mv |
2019-05-27T14:25:24Z |
dc.date.available.none.fl_str_mv |
2019-05-27T14:25:24Z |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
acceptedVersion |
dc.identifier.uri.spa.fl_str_mv |
https://hdl.handle.net/11323/4721 |
dc.identifier.instname.spa.fl_str_mv |
Corporación Universidad de la Costa |
dc.identifier.reponame.spa.fl_str_mv |
REDICUC - Repositorio CUC |
dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.cuc.edu.co/ |
url |
https://hdl.handle.net/11323/4721 https://repositorio.cuc.edu.co/ |
identifier_str_mv |
Corporación Universidad de la Costa REDICUC - Repositorio CUC |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.spa.fl_str_mv |
doi: 10.26633/RPSP.2017.124. |
dc.relation.references.spa.fl_str_mv |
1. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. 2. Muñoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24S3:S3/1-S3/10. 3. Denny L, Quinn M, Sankaranayanan R. Screening for cervical cancer in developing countries. Vaccine. 2006;24S3:S3/71- S3/77. 4. Centers for Disease Control and Prevention. Progress towards implementation of human papillomavirus vaccination – the Americas 2006–2010. MMWR. 2011;60(40): 1382–4. 5. Petrosky E, Bocchini J, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of a 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR 2015; 64:300–4 6. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465–92. 7. Pan American Health Organization. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article& id=9394%3A2014-80percent-adolescentes-americas-vacuna-vph-brasil&catid=740%3Anews-pressreleases&Itemid=1926&lang=en. Accessed 26 February 2016. 8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4: e453–63. 9. Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H, et al. Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15:565–80. 10. Stoto M, Cosler S. Evaluation of public health interventions. In: Lloyd F, Morrow C, Mays G, eds. Public health administration: principles for population-based management. 2nd edition. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2007: 495–544. Available from: file:///C:/Users/docisp/Downloads/ Evaluation_of_Public_Health_Interventions%20(2).pdf. Accessed 26 February 2016. 11. Sabin Vaccine Institute. Human papillomavirus (HPV) and related burden of disease in Latin American and the Caribbean. January 2009. Available from: http:// www.sabin.org/updates/resources/human-papillomavirus-hpv-and-related -burdendisease-latin-america-and-caribbean Accessed 8 March 2016. 12. Economic Commission for Latin America and the Caribbean. Demographic bulletin. Latin America and Caribbean. Population estimation and projections. 1950–2050. Available from: http://www.cepal.org/ publicaciones/xml/7/14347/lcg2225.pdf Accessed 26 February 2016. 13. Ministerio de Salud de Argentina. Manual del vacunador 2017. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000926cnt-2016– 12_lineamientos-VPH.pdf Accessed 2 June 2017. 14. Ministério da Saude. Nota informativa sobre mudanças no calendário nacional de vacinação para o ano de 2017. Available from: http://portalarquivos.saude. gov.br/images/pdf/2016/outubro/20/ Nota-Informativa-311-CalendarioNacional-de-Vacinacao-2017.pdf Accessed 2 June 2017. 15. Ministerio de Salud de Chile. Vacunación contra el virus del papiloma humano. Available from: http://web.minsal.cl/vacunacion-contra-el-virus-del-papiloma-humano/ Accessed 2 June 2017. 16. Ministerio de Salud de Panamá. MINSA lanza vacuna contra Virus del Papiloma Humano (VPH) en niños. Available from: http://www.minsa.gob.pa/noticia/minsa-lanza-vacuna-contra-virus-del-papiloma-humano-vph-en-ninos Accessed 2 June 2017. 17. Ministerio de Salud del Perú. Plan de Salud Escolar: más de 475 mil niñas serán vacunadas contra el Virus de Papiloma Humano. 17 March 2015. Available from: http://www.minsa. gob.pe/?op=51¬a=16252 Accessed 14 March 2016. 18. Ministerio de Salud del Perú. Minsa promueve vacuna que protege de cuatro tipos de Virus de Papiloma Humano (VPH) para niñas del quinto y sexto grado. Available from: http://www.minsa.gob. pe/?op=51¬a=20909 Accessed 14 July 2017. 19. Organización Panamericana de la Salud/ Uruguay. MSP inició vacunación contra HPV en adolescentes para prevenir cáncer de cuello de útero. Available from: http://www. paho.org/uru/index.php?option=com_ content&view=article&id=672:msp-iniciovacunacion-contra-hpv-adolescentesprevenir-cancer-cuello-utero-&Itemid=340 Accessed 14 March 2016. 20. El Observador. Vacuna contra el VPH obligatoria para niñas desde el año que viene. 29 September 2016. Available from: http://www.elobservador.com. uy/vacuna-contra-el-hpv-obligatoria-ninas-el-ano-que-viene-n978032 Accessed 2 June 2017. 21. Organización Panamericana de la Salud/ Bolivia. Bolivia introduce la vacuna contra el Virus del Papiloma Humano en su esquema nacional de vacunación. Available from: http://www.paho.org/bol/ index.php?option=com_content&view=article&id=1971:bolivia-introduce-lavacuna-contra-el-virus-del-papilomahumano-en-su-esquema-nacional-devacunacion&Itemid=481 Accessed 2 June 2017. 22. Organización Panamericana de la Salud/ República Dominicana. República Dominicana inicia su Semana de Vacunación de las Américas con la introducción de la vacuna contra el VPH. Available from: http://www.paho.org/dor/index. php?option=com_content&view=article&id=2433:republica-dominicana-inicia -su-semana-de-vacunacion-de-las-americas-con-la-introduccion-de-la-vacunacontra-el-vph&Itemid=362 Accessed 2 June 2017. 23. Secretaria de Salud de Honduras. Salud introduce vacuna del Virus del Papiloma Humano (VPH) para niñas de 11 años. Available from: http://www. salud.gob.hn/web/index.php/component/k2/item/347-salud-introduce-vacuna-del-virus-del-papiloma-humanovph-para-ninas-de-11-anos Accessed 2 June 2017. 24. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine. 2010;28S:A13–A17. 25. Tambini G, Andrus J, Fitzsimmons J, Roses Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Rev Panam Salud Publica. 2006;20(1):54–9. 26. Organización Panamericana de la Salud. Precios del Fondo Rotatorio. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article&id=9561%3A2014-revolving-fund -prices&catid=839%3Arevolving -fund&Itemid=40714&lang=es Accessed 2 June 2017. 27. Palacio-Mejía L, Rangel-Gómez G, Hernández-Avila M, Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45(S3):S315–25. 28. Goldie S, Diaz M, Constenla D, Alvis N, Andrus J, Kima SJ. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26S:L59–72. 29. Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1–8. 30. Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Hum Vaccin. 2011;7(12):1374–86. 31. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(19):241–68. 32. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(47):pii=19730. 33. Castellsagué X, Ault K, Bosch X, Brown D, Cuzick J, Ferris D, Joura E, et al. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–9 34. Sanchez-Gomez L, Yepez-Lujan F, Hernandez-Florez L. La vacunación contra el virus del papiloma humano en Colombia. Rev Gerenc Polit Salud. 2014; 13(27):5–9 |
dc.rights.spa.fl_str_mv |
Attribution-NonCommercial-ShareAlike 4.0 International |
dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
Attribution-NonCommercial-ShareAlike 4.0 International http://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.publisher.spa.fl_str_mv |
Rev Panam Salud Publica |
institution |
Corporación Universidad de la Costa |
bitstream.url.fl_str_mv |
https://repositorio.cuc.edu.co/bitstreams/740e94a4-09f2-4498-8fba-e3df86f6f77b/download https://repositorio.cuc.edu.co/bitstreams/c092d623-8997-4ee9-aed6-2e1b63d09872/download https://repositorio.cuc.edu.co/bitstreams/d1220cf1-293b-4189-9fb7-0b87f20ba614/download https://repositorio.cuc.edu.co/bitstreams/efeaa581-0d55-4ac9-a7f7-6d4d610e2615/download https://repositorio.cuc.edu.co/bitstreams/9e714a91-d425-4749-bb51-527064ed55e7/download |
bitstream.checksum.fl_str_mv |
3b8246c4f8ac3b8e7c12555dd49b130c 934f4ca17e109e0a05eaeaba504d7ce4 8a4605be74aa9ea9d79846c1fba20a33 7f79248ca319ecdca5cbf7ae2e7eda7b 7ce2e5231557fa6a48b770c159c9af32 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio de la Universidad de la Costa CUC |
repository.mail.fl_str_mv |
repdigital@cuc.edu.co |
_version_ |
1811760746334257152 |
spelling |
De la Hoz Restrepo, FernandoAlvis Guzman, NelsonDe la Hoz Gomez, AlejandroRuiz, Cuauhtémoc2019-05-27T14:25:24Z2019-05-27T14:25:24Z2017https://hdl.handle.net/11323/4721Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of countries in Latin America and the Caribbean (LAC). Methods. We reviewed national and regional sources of information to identify LAC countries with and without universal HPV vaccination, along with the year of introduction, type of HPV vaccine, vaccination scheme, age groups targeted, and coverage level reached. Incidence rates of cervical cancer were compared across countries with and without an HPV vaccination program, in order to identify inequities in access to HPV vaccines. Results. So far, 10 LAC countries have supplied data on their vaccination policies and vaccination coverage rates to the Pan America Health Organization. The majority of those 10 started their vaccination programs using quadrivalent vaccine. Only Chile, Ecuador, and Mexico started their programs using a two-dose scheme. However, by the end of 2016, most of the other countries had switched from a three-dose to a two-dose scheme. Different age groups are targeted in the various programs. Some countries vaccinate one-year birth cohorts, while others vaccinate multiple-year birth cohorts. By the end of 2014, coverage with at least two doses ranged from a low of 2% to a high of 86%. With the exception of Venezuela, the LAC countries with the largest populations introduced universal HPV vaccination between 2010 and 2014. Despite the progress that has occurred in some LAC countries, there are still 10 LAC nations with cervical cancer rates above the LAC average (21.2 cases per 100 000) that have not introduced an HPV vaccine in their EPI. Conclusions. With several key adjustments, HPV vaccination programs across Latin America and the Caribbean could be substantially strengthened. Ongoing monitoring of HPV infection outcomes is needed in order to assess the impact of different vaccination policies.Los objetivos Hay tres vacunas altamente eficaces disponibles para prevenir la infección del virus del papiloma humano (VPH), y se han introducido en muchos países del mundo. Este artículo describe los avances y desafíos en la introducción de vacunas contra el VPH en el Programa Ampliado de Inmunización (EPI) de los países de América Latina y el Caribe (LAC). Los metodos Revisamos las fuentes nacionales y regionales de información para identificar los países de ALC con y sin la vacunación universal contra el VPH, junto con el año de introducción, el tipo de vacuna contra el VPH, el esquema de vacunación, los grupos de edad seleccionados y el nivel de cobertura alcanzado. Las tasas de incidencia de cáncer cervical se compararon entre países con y sin un programa de vacunación contra el VPH, con el fin de identificar las inequidades en el acceso a las vacunas contra el VPH. Resultados Hasta ahora, 10 países de ALC han proporcionado datos sobre sus políticas de vacunación y tasas de cobertura de vacunación a la Organización Panamericana de la Salud. La mayoría de esos 10 comenzaron sus programas de vacunación utilizando la vacuna cuadrivalente. Solo Chile, Ecuador y México comenzaron sus programas utilizando un esquema de dos dosis. Sin embargo, a finales de 2016, la mayoría de los otros países habían cambiado de un esquema de tres dosis a uno de dos dosis. Diferentes grupos de edad son objetivo en los distintos programas. Algunos países vacunan cohortes de nacimiento de un año, mientras que otros vacunan cohortes de nacimiento de varios años. A finales de 2014, la cobertura con al menos dos dosis oscilaba entre un mínimo del 2% y un máximo del 86%. Con la excepción de Venezuela, los países de ALC con las poblaciones más grandes introdujeron la vacunación universal contra el VPH entre 2010 y 2014. A pesar del progreso que se ha producido en algunos países de ALC, todavía hay 10 países de ALC con tasas de cáncer cervical por encima del promedio de ALC (21,2 casos). por cada 100 000) que no han introducido una vacuna contra el VPH en su EPI. Conclusiones. Con varios ajustes clave, los programas de vacunación contra el VPH en América Latina y el Caribe podrían fortalecerse sustancialmente. El monitoreo continuo de los resultados de la infección por VPH es necesario para evaluar el impacto de las diferentes políticas de vacunación. Políticas de vacunación.De la Hoz Restrepo, Fernando-e374ad59-e159-4dc6-906d-773d4be3e0b1-0Alvis Guzman, Nelson-8bd90d52-51ab-4917-ad57-b2424f106eac-0De la Hoz Gomez, Alejandro-7330aa2e-0ec6-453c-9efa-5e35415cf578-0Ruiz, Cuauhtémoc-15f494ca-8d25-440a-9a11-205c6829a51a-0engRev Panam Salud Publicadoi: 10.26633/RPSP.2017.124.1. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. 2. Muñoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24S3:S3/1-S3/10. 3. Denny L, Quinn M, Sankaranayanan R. Screening for cervical cancer in developing countries. Vaccine. 2006;24S3:S3/71- S3/77. 4. Centers for Disease Control and Prevention. Progress towards implementation of human papillomavirus vaccination – the Americas 2006–2010. MMWR. 2011;60(40): 1382–4. 5. Petrosky E, Bocchini J, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of a 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR 2015; 64:300–4 6. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465–92. 7. Pan American Health Organization. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article& id=9394%3A2014-80percent-adolescentes-americas-vacuna-vph-brasil&catid=740%3Anews-pressreleases&Itemid=1926&lang=en. Accessed 26 February 2016. 8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4: e453–63. 9. Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H, et al. Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15:565–80. 10. Stoto M, Cosler S. Evaluation of public health interventions. In: Lloyd F, Morrow C, Mays G, eds. Public health administration: principles for population-based management. 2nd edition. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2007: 495–544. Available from: file:///C:/Users/docisp/Downloads/ Evaluation_of_Public_Health_Interventions%20(2).pdf. Accessed 26 February 2016. 11. Sabin Vaccine Institute. Human papillomavirus (HPV) and related burden of disease in Latin American and the Caribbean. January 2009. Available from: http:// www.sabin.org/updates/resources/human-papillomavirus-hpv-and-related -burdendisease-latin-america-and-caribbean Accessed 8 March 2016. 12. Economic Commission for Latin America and the Caribbean. Demographic bulletin. Latin America and Caribbean. Population estimation and projections. 1950–2050. Available from: http://www.cepal.org/ publicaciones/xml/7/14347/lcg2225.pdf Accessed 26 February 2016. 13. Ministerio de Salud de Argentina. Manual del vacunador 2017. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000926cnt-2016– 12_lineamientos-VPH.pdf Accessed 2 June 2017. 14. Ministério da Saude. Nota informativa sobre mudanças no calendário nacional de vacinação para o ano de 2017. Available from: http://portalarquivos.saude. gov.br/images/pdf/2016/outubro/20/ Nota-Informativa-311-CalendarioNacional-de-Vacinacao-2017.pdf Accessed 2 June 2017. 15. Ministerio de Salud de Chile. Vacunación contra el virus del papiloma humano. Available from: http://web.minsal.cl/vacunacion-contra-el-virus-del-papiloma-humano/ Accessed 2 June 2017. 16. Ministerio de Salud de Panamá. MINSA lanza vacuna contra Virus del Papiloma Humano (VPH) en niños. Available from: http://www.minsa.gob.pa/noticia/minsa-lanza-vacuna-contra-virus-del-papiloma-humano-vph-en-ninos Accessed 2 June 2017. 17. Ministerio de Salud del Perú. Plan de Salud Escolar: más de 475 mil niñas serán vacunadas contra el Virus de Papiloma Humano. 17 March 2015. Available from: http://www.minsa. gob.pe/?op=51¬a=16252 Accessed 14 March 2016. 18. Ministerio de Salud del Perú. Minsa promueve vacuna que protege de cuatro tipos de Virus de Papiloma Humano (VPH) para niñas del quinto y sexto grado. Available from: http://www.minsa.gob. pe/?op=51¬a=20909 Accessed 14 July 2017. 19. Organización Panamericana de la Salud/ Uruguay. MSP inició vacunación contra HPV en adolescentes para prevenir cáncer de cuello de útero. Available from: http://www. paho.org/uru/index.php?option=com_ content&view=article&id=672:msp-iniciovacunacion-contra-hpv-adolescentesprevenir-cancer-cuello-utero-&Itemid=340 Accessed 14 March 2016. 20. El Observador. Vacuna contra el VPH obligatoria para niñas desde el año que viene. 29 September 2016. Available from: http://www.elobservador.com. uy/vacuna-contra-el-hpv-obligatoria-ninas-el-ano-que-viene-n978032 Accessed 2 June 2017. 21. Organización Panamericana de la Salud/ Bolivia. Bolivia introduce la vacuna contra el Virus del Papiloma Humano en su esquema nacional de vacunación. Available from: http://www.paho.org/bol/ index.php?option=com_content&view=article&id=1971:bolivia-introduce-lavacuna-contra-el-virus-del-papilomahumano-en-su-esquema-nacional-devacunacion&Itemid=481 Accessed 2 June 2017. 22. Organización Panamericana de la Salud/ República Dominicana. República Dominicana inicia su Semana de Vacunación de las Américas con la introducción de la vacuna contra el VPH. Available from: http://www.paho.org/dor/index. php?option=com_content&view=article&id=2433:republica-dominicana-inicia -su-semana-de-vacunacion-de-las-americas-con-la-introduccion-de-la-vacunacontra-el-vph&Itemid=362 Accessed 2 June 2017. 23. Secretaria de Salud de Honduras. Salud introduce vacuna del Virus del Papiloma Humano (VPH) para niñas de 11 años. Available from: http://www. salud.gob.hn/web/index.php/component/k2/item/347-salud-introduce-vacuna-del-virus-del-papiloma-humanovph-para-ninas-de-11-anos Accessed 2 June 2017. 24. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine. 2010;28S:A13–A17. 25. Tambini G, Andrus J, Fitzsimmons J, Roses Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Rev Panam Salud Publica. 2006;20(1):54–9. 26. Organización Panamericana de la Salud. Precios del Fondo Rotatorio. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article&id=9561%3A2014-revolving-fund -prices&catid=839%3Arevolving -fund&Itemid=40714&lang=es Accessed 2 June 2017. 27. Palacio-Mejía L, Rangel-Gómez G, Hernández-Avila M, Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45(S3):S315–25. 28. Goldie S, Diaz M, Constenla D, Alvis N, Andrus J, Kima SJ. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26S:L59–72. 29. Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1–8. 30. Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Hum Vaccin. 2011;7(12):1374–86. 31. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(19):241–68. 32. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(47):pii=19730. 33. Castellsagué X, Ault K, Bosch X, Brown D, Cuzick J, Ferris D, Joura E, et al. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–9 34. Sanchez-Gomez L, Yepez-Lujan F, Hernandez-Florez L. La vacunación contra el virus del papiloma humano en Colombia. Rev Gerenc Polit Salud. 2014; 13(27):5–9Attribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Papillomavirus vaccinesHealth policyHealth services researchProgram evaluationImmunization programsWest IndiesLatin AmericaVacunas contra el virus del papilomaPolítica de saludInvestigación en servicios de saludPrograma de evaluaciónProgramas de inmunizacionIndias OccidentalesAmérica latinaPolicies and processes for human papillomavirus vaccination in Latin America and the CaribbeanPolíticas y procesos para el humano. vacunación contra el virus del papiloma en latín América y el caribeArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionPublicationORIGINALPolicies and processes for human.pdfPolicies and processes for human.pdfapplication/pdf2035134https://repositorio.cuc.edu.co/bitstreams/740e94a4-09f2-4498-8fba-e3df86f6f77b/download3b8246c4f8ac3b8e7c12555dd49b130cMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://repositorio.cuc.edu.co/bitstreams/c092d623-8997-4ee9-aed6-2e1b63d09872/download934f4ca17e109e0a05eaeaba504d7ce4MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstreams/d1220cf1-293b-4189-9fb7-0b87f20ba614/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILPolicies and processes for human.pdf.jpgPolicies and processes for human.pdf.jpgimage/jpeg60435https://repositorio.cuc.edu.co/bitstreams/efeaa581-0d55-4ac9-a7f7-6d4d610e2615/download7f79248ca319ecdca5cbf7ae2e7eda7bMD55TEXTPolicies and processes for human.pdf.txtPolicies and processes for human.pdf.txttext/plain42828https://repositorio.cuc.edu.co/bitstreams/9e714a91-d425-4749-bb51-527064ed55e7/download7ce2e5231557fa6a48b770c159c9af32MD5611323/4721oai:repositorio.cuc.edu.co:11323/47212024-09-17 10:56:34.185http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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 |